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Abstract
Introduction: We have taken advantage of the large screening capacity of a multiplex immunoassay to better
define the respective contribution of articular versus systemic cytokines in experimental arthritis.
Methods: We performed a follow up (from 7 hours to 14 days) multiplex analysis of 24 cytokines in synovial fluid
and sera of rats developing Antigen-Induced Arthritis (AIA) and confronted their protein level changes with
molecular, biochemical, histological and clinical events occurring in the course of the disease.
Results: The time-scheduled findings in arthritic joints correlated with time-dependent changes of cytokine
amounts in joint effusions but not with their blood levels. From seven hours after sensitization, high levels of
chemokines (MCP-1, MIP1a, GRO/KC, RANTES, eotaxin) were found in synovial fluid of arthritic knees whereas
perivascular infiltration occurred in the synovium; local release of inflammatory cytokines (IFNg, IL-1b, IL-6) preceded
the spreading of inflammation and resulted in progressive degradation of cartilage and bone. Finally a local
overexpression of several cytokines/adipocytokines poorly described in arthritis (IL-13, IL-18, leptin) was observed.
Conclusions: Distinct panels of cytokines were found in arthritic fluid during AIA, and the expected effect of
mediators correlated well with changes occurring in joint tissues. Moreover, multiplex analysis could be helpful to
identify new pathogenic mediators and to elucidate the mechanisms supporting the efficacy of putative targeted
therapies.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
autoimmune disorder [1] characterized by infiltration of
neutrophils and lymphocytes into the synovial tissue and
joint fluid [2,3], leading to secondary cartilage and bone
destruction [4]. Several mediators, including proinflam-
matory and immunomodulatory cytokines, growth fac-
tors, and chemotactic cytokines (chemokines), have been
implicated in the inflammatory process of RA. Although
the cytokine network suggests that mediators can be
categorized depending on their primary or secondary
role in the disease process [5], questions about the fine
tuning of cytokine expression during autoimmune
arthritis remain. Cytokines such as interleukin-1-beta
(IL-1b), tumor necrosis factor-alpha (TNF-a), and inter-
leukin-6 (IL-6) [6,7] have been shown to display potent
proinflammatory actions and to contribute to the patho-
genesis of RA [8] or experimental arthritis, particularly to
cartilage and bone damages [9]. Thus, targeted therapies
against these cytokines were shown to be relevant in
murine and rat models of RA [10,11] before being shown
to be efficient therapies in the clinics [12]. Anti-TNFa
therapies are now widely used [13] and their clinical ben-
efits are well recognized despite an increased risk of
infectious disease such as tuberculosis [14]. However,
regardless of the therapy used, some patients treated with
anticytokine biotherapies remain refractory or become
non-responders to the treatment. Therefore, there is a
need to use combined therapies or to search for new
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therapeutic strategy aiming to control additional media-
tors or both [15].
Antigen-induced arthritis (AIA), a severe monoarticu-
lar chronic arthritis induced by intra-articular adminis-
tration of methylated bovine serum albumin (mBSA) in
sensitized animals, is an immune-mediated joint inflam-
mation reproducing some histopathological findings of
RA, such as infiltration of the synovial membrane by
CD4+ T cells and macrophages and a disease course with
discernable phases [16,17]. The kinetics and pathogenic
roles of cytokines and chemokines have not been exten-
sively investigated in AIA, and analysis of their local
expression could help to elucidate the mechanisms sup-
porting arthritis [18]. Earlier studies of the expression of
mediators in this model were carried out on joint homo-
genates [19,20] mainly because the available amounts of
tissue samples were too small to allow an extensive analy-
sis. In addition, these data considered the mRNA levels
mainly and were not able to distinguish mature cytokines
from their precursors, thus overestimating the amount of
several active mediators with a possible pathogenic role.
When studies focused on the cytokine levels in joint fluid
of arthritic rodents, a limited number of mediators were
addressed [19,21] or assays were restricted to cytokines,
such as TNF-a, IL-1b, or IL-6, that have a well-known
pathogenic role [22].
In the present study, we investigated the kinetics of 24
cytokines in rats developing AIA using a multiplex
immunoassay that allowed a highly sensitive biological
follow-up of multiple mediators from a limited amount
of biological sample [15]. Levels of mediators were
checked concomitantly in the knee joint - that is, the
synovial fluid (SF) - and the bloodstream to establish the
sequence and display of cytokine activation in RA-like
conditions and to correlate the time-dependent changes
of mediators with clinical and histological hallmarks of
arthritis. We observed induction of IL-1b, IL-6 and IL-
17, cytokines already described as key players in the
arthritis process and clinically used as therapeutic targets.
Interestingly, we also found expression of mediators that,
to date, have no known involvement in this pathology.
Indeed, the chemokines eotaxin and growth-related
oncogene/keratinocyte chemoattractant (GRO/KC) and
the T helper 2 (Th2)-associated cytokines IL-13 and IL-9
were highly induced in arthritic SFs and represent new
potential targets for RA treatment.
Materials and methods
Animals
All experiments were carried out in barrier-maintained
male Wistar Han rats (150 to 175 g on day 0, or D0)
purchased from Charles River Laboratories (L’Arbresle,
France). Animals were allowed to acclimatize for at least
1 week after their arrival in our facility. Animals were
housed in groups of five in solid-bottomed plastic cages
with access to tap water and standard rodent pelleted
chow (A04; Scientific Animal Food & Engineering, Ville-
moisson-sur-orge, France) ad libitum. Room tempera-
ture was set at 23 ± 1°C, and animals were subjected to
a 12-hour light cycle (with lights on from 6 a.m. to 6 p.
m.). All experiments were performed in accordance with
national animal care guidelines and were preapproved
by a local ethics committee. Arthritis induction, blood
sampling, and necropsy were performed under general
anesthesia by using volatile anesthetics (AErrane™; Bax-
ter SA, Maurepas, France).
Induction of antigen arthritis
Animals were immunized 21 and 14 days before the anti-
genic challenge by a subcutaneous flank injection of
250 μL of a suspension, which contained 0.5 g of methy-
lated bovine serum albumin (mBSA) (Sigma-Aldrich,
Deisenhofen, Germany) and which was resuspended in
125 μL of saline and emulsified with 125 μL of complete
Freund’s adjuvant (2 mg/mL Mycobacterium tuberculosis;
Difco Laboratories Inc., now part of Becton Dickinson
and Company, Franklin Lakes, NJ, USA). On D0, AIA
was induced by a single intra-articular injection of 0.5 mg
of mBSA (50 μL of 10 mg/mL mBSA dissolved in 0.9%
NaCl) into the right knee joint; the contralateral knee
received 50 μL of 0.9% NaCl. Control rats were immu-
nized with the same protocol but received an intra-
articular injection of 50 μL of 0.9% NaCl in both knees
on D0.
Scoring of arthritis
The disease course was monitored by the repeated
assessment of knee joint width by using a caliper (Kroe-
plin Längenmesstechnik, Schlüchtern, Germany). Raw
data were used to estimate joint circumference by using
the geometric formula of ellipse circumference, 2πX to
the power of √ (a2 + B2), in which a is knee height and B
is knee breadth. The results were representative of joint
swelling and expressed (in millimeters) as the difference
between the joint size at a given day compared with that
measured just before arthritis induction (D0).
Weight-bearing assessment protocol
Hind-limb weight bearing was determined by using an
incapacitation tester (Linton Instrumentation, Norfolk,
UK) consisting of a dual-channel weight averager. Weight
distribution was measured between sensitized (intra-
articular injection of mBSA) and contralateral (saline-
injected) hind limbs and was used as an index of joint dis-
comfort in the arthritic knee. Rats were placed carefully in
an angled Plexiglas chamber positioned so that each hind-
paw rested on a separate force plate. Care was taken to
ensure that the weight of the animal was directed onto the
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force plates and not dissipated through the walls of the
chamber. The force exerted by each hind limb (measured
in grams) was averaged over a 5-second period. Each data
point is the mean of three readings. The percentage of
weight distributed onto the sensitized (arthritic) hind limb
was calculated by the following equation: [weight on ipsi-
lateral hind limb/(weight on ispsilateral + weight on con-
tralateral)] × 100 [23]. The weight-bearing distribution of
arthritic rats was compared with that of control rats
(injected bilaterally with saline into the knee joints).
Histological examination
Knee joints were collected at necropsy, fixed immediately
for 24 hours in 4% paraformaldehyde, decalcified in rapid
bone decalcifier (RDO; Apex Engineering, Plainfield, IL,
USA) for 6 hours at room temperature, and further fixed
in 4% paraformaldehyde before embedding in paraffin.
Sections (5 μm thick) were rehydrated in a graded etha-
nol series and stained with either hematoxylin/eosin/
safran, safranin O-fast green, or May-Grünwald Giemsa.
The histological characteristics of articular cartilage,
bone, and peri-articular soft tissues were scored indepen-
dently by two observers who were blind to the samples.
Cartilage degradation was graded from 0 to 3, where 0 =
fully stained cartilage, 1 = loss of proteoglycan staining in
the superficial layer, 2 = complete loss of proteoglycan
staining, and 3 = complete loss of cartilage. The following
morphological criteria were used for bone erosion:
0 = normal, 1 = mild loss of cortical bone at few sites,
2 = moderate loss of cortical and trabecular bone, and
3 = marked loss of bone at many sites. Synovium from
the knee joint was graded by using a scoring technique
adapted from Rooney and colleagues [24]. Briefly, sam-
ples were evaluated on a scale from 0 to 4 (0 = normal
and 4 = major changes) for hyperplasia of synovial fibro-
blasts (depth of lining layer), fibrosis (percentage of repla-
cement of loose connective tissue), angiogenesis (number
of proliferating blood vessels), perivascular infiltrates of
lymphocytes (percentage of vessels surrounded by lym-
phocytes), and tissue infiltration by lymphocytes (size of
aggregates and percentage of infiltrating cells).
Assessment of cytokine expression
Biological fluid sampling
Blood (300 μL) was collected by sampling of the tail
veins at seven time points: D0, 7 hours (H7), D1, D2, D3,
D7, and D14. As we observed no significant difference
between cytokine pattern measured in plasma versus
serum samples in a preliminary set of experiments (not
presented in this paper), we opted for cytokine analysis
in serum as this method is widely accepted in cytokine
pattern determination in the context of diagnosis or
prognosis of RA or both [25,26]. After clotting for 1
hour at room temperature, samples were centrifuged for
10 minutes at 3,000g at room temperature. Obviously
hemolyzed samples were discarded as they resulted in a
high aggregation of beads. Serum was collected and fro-
zen at -80°C until analysis.
Joint fluid sampling was carried out after killing of ani-
mals at corresponding times. Briefly, the patellar ligament
was cut and the articular cavity was incised perpendicu-
larly to the patella. The SF was then collected by impreg-
nation of standardized small pieces (4 mm2) of filter
paper (Schleicher & Schuell GmbH, Dassel, Germany).
This technique was chosen because of the inability to
aspirate joint fluid from rodent joints, especially saline-
injected knees. The saturation of filter pieces with SF
allows the circumvention of the variation in a sample
volume and was applied successfully to the monitoring of
nitric oxide release in rat arthritis [27]. To prevent any
proteolytic cleavage of cytokines in arthritic fluids, these
paper pieces were left for 12 hours at 4°C in 150 μL of
PBS containing a cocktail of protease inhibitors (Com-
plete Mini™; Roche, Basel, Switzerland, Roche reference
number 11 836 153 001, one tablet for 10 mL). After
initial and final agitations for 30 seconds on a mechanic
stirrer, the ‘joint-derived’ eluates (referred to as SF) were
frozen at -80°C until processing. Samples were assessed
with a hemoglobin detection reagent strip to exclude any
blood contamination. Briefly, 10 μL of diluted samples
(1/10 in PBS) was dropped on a Hemastix® reagent strip
(limit of detection of 0.015 to 0.062 mg/dL, which is
approximately equivalent to 5 to 20 red blood cells per
microliter). Positive samples were excluded from multi-
plex analysis.
Multiplex immunoassay
Levels of 24 cytokines - IL-1a, IL-1b, IL-2, IL-4, IL-5,
IL-6, IL-9, IL-10, IL-12p(70), IL-13, IL-17, IL-18, leptin,
GRO/KC, TNFa, interferon gamma (IFNg), GM-CSF,
RANTES, MCP-1, macrophage inflammatory protein-1-
alpha (MIP-1a), G-CSF, IP-10, eotaxin, and VEGF - were
determined in both SF (sensitized and contralateral) and
serum at each time point by means of a Milliplex™ MAP
kit (Millipore, Billerica, MA, USA). Millipore multiscreen
96-well filter plates for multiplex cytokine kits were used.
Rat cytokine standards were diluted in a ‘serum matrix’
solution (optimized protein concentration) for serum
sample determination and in PBS for SF measurements.
For each time point, data were obtained from five rats.
Each animal sample was run in triplicate in accordance
with the protocol of the manufacturer [15], and the final
results presented here are representative of three inde-
pendent experiments. Data were collected by using Lumi-
nex-100 software version 1.7 (Luminex, Austin, TX,
USA), and analysis was performed with the MasterPlex
QT 1.0 system (MiraiBio, Alameda, CA, USA). A five-
parameter regression formula was used to calculate the
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sample concentrations from the standard curves. Data
were analyzed by using either 5- or 4-parameter logistic
or spline curve-fitting method as recommended by the
manufacturer. Type of curve-fitting method was chosen
for each cytokine with respect to the lowest residual var-
iance (< 5%).
mRNA levels of selected mediators in synovium
Tissue sampling and preparation
Articular synovium, cartilage of patella were collected
aseptically at necropsy and immediately frozen. Frozen
tissues, kept at -80°C before extraction, were homoge-
nized immediately after thawing by using a dispersing
system and mixed with 350 μL of RLT buffer added
with b-mercapto-ethanol. Samples were then passed on
Qiashredder columns (RNeasy kit; Qiagen, Courtaboeuf,
France), and mRNAs were extracted with the RNeasy
kit in accordance with manufacturer recommendations.
Real-time reverse transcriptase-polymerase chain reaction
mRNA (0.5 μg) of each sample was then reverse-tran-
scribed for 90 minutes at 37°C with 200 U of Moloney
murine leukemia virus reverse transcriptase (Invitrogen
Corporation, Carlsbad, CA, USA) and oligo(dT) primers
(Eurogentec, Liège, Belgium) in accordance with the
recommendations of the suppliers. Expressions of MCP-1
(chemokine) and IL-1b, IL-6, and TNF-a (proinflamma-
tory cytokines) and VEGF (growth factor) were quantified
by real-time polymerase chain reaction (PCR) with the
Lightcycler® (Roche) technology and the SYBR green mas-
ter mix system® (Qiagen). After amplification, a melting
curve was constructed to determine the melting tempera-
ture of each PCR product. The mRNA levels of each gene
of interest and of the ribosomal protein S29, chosen as a
housekeeping gene, were determined in parallel for each
sample. Results are expressed with the delta delta thresh-
old cycle (Ct) method. The gene-specific primer pairs used
were as follows: MCP-1, forward 5’-CAGATCTCTC
TTCCTCCACCACTAT-3’, reverse 5’-GCATTAACTG-
CATCTGGCTGAGACAGC-3’; IL-1b, forward 5’- CTT
CCCCAGGACATGCTAGG-3’, reverse 5’-CAAAGG
CTTCCCCTGGAGAC-3’; IL-6, forward 5’-CCGGAGAG-
GAGACTTCACAG-3’, reverse 5’-ACAGTGCATCA
TCGCTGTTC-3’; TNF-a, forward 5’-AGCCCTGGTAT-
GAGCCCATGTA-3’, reverse 5’- CCGGACTCCGTGA
TGTCTAAGT-3’; and VEGF, forward 5’- CACATCTG-
CAAGTACGTTCGTTTA-3’, reverse 5’- CAGAGCGGA-
GAAAGCATTTGTT-3’.
Assessment of proteoglycan metabolism in patellar
cartilage
Proteoglycan synthesis was studied by an ex vivo incor-
poration of Na2
35SO4 into patellar cartilage. At necropsy,
patellas were collected aseptically, dissected from peri-
articular tissues, and then pulsed for 3 hours at 37°C in a
5% CO2 atmosphere with 0.6 μCi/mL Na2
35SO4 (Amer-
sham, Les Ulis, France) in RPMI-Hepes 1640 medium
supplemented with 2 mM L-glutamine, 100 IU/mL of
penicillin, and 100 μg/mL of streptomycin (Life Technolo-
gies, Cergy-Pontoise, France). After five washings in saline,
patellas were fixed overnight in 0.5% cetylpyridinium
chloride (Sigma-Aldrich, Saint Quentin-Fallavier, France)
in 10% (vol/vol) phosphate-buffered formalin and then
decalcified in 5% (vol/vol) formic acid for 7 hours at room
temperature. Biopsy punches, 2 mm in diameter, were
taken from the central part of the patellas before dissolu-
tion overnight in Solvable (Packard, Rungis, France).
35S-proteoglycan content was measured by liquid scintilla-
tion counting (Hionic Fluor; Packard), data are expressed
as the percentage of variation from healthy controls, and a
negative value represents a decrease of proteoglycan
synthesis [28].
Statistical analysis
All results, except in Figure 2 (fold changes), are expressed
as mean ± standard error of the mean. All analyses and
figure editing were carried out by using GraphPad Prism
(release 4; GraphPad Software, Inc., San Diego, CA, USA).
The Student t test was used to compare a batch with its
own control and analysis of variance with post hoc Bonfer-
roni when required (that is, with groups of at least three).
Results
Clinical features of antigen-induced arthritis
All animals developed signs of arthritis from 7 hours after
intra-articular injection of mBSA. A progressive joint swel-
ling was observed in sensitized knees and peaked between
D2 and D4 and then decreased slowly from D5 to D14
(Figure 1a). At the same time, a significant loss in body-
weight gain was observed in arthritic rats compared with
controls and reached 20.5% ± 3.5% at D14 (data not
shown).
Hind-limb weight distribution
Rats injected bilaterally with saline distributed their body
weight between both hind limbs, as shown by an average
weight distribution of 50% ± 4% between the two legs (Fig-
ure 1b). In arthritic rats, a shift in weight distribution
occurred toward the saline-injected contralateral limb
from 7 hours after mBSA injection. A maximal level of
incapacitation was observed by D1 with rats placing only
16% ± 2% of their body weight on the sensitized leg
(Figure 1b). Thereafter, joint discomfort remained stable
until D14.
Proteoglycan synthesis in patellar cartilage
In arthritic rats, a significant depletion of proteoglycan
synthesis was observed from 1 to 3 days after the anti-
genic challenge (Figure 1c). Proteoglycan loss varied
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between 35% ± 2% and 29% ± 5% at these times. At a
later time, proteoglycan synthesis returned to a normal
level in mBSA-injected knees (Figure 1c).
Mediators mRNA expression in joint tissues
To check for the relevance of proteins found in the SF to
molecular changes occurring in inflamed synovium,
mRNA expression profiles of selected cytokines were
analyzed in synovial membranes of arthritic rats (Table 1).
These cytokines were representative of different functional
classes: one chemokine (MCP-1), three proinflammatory
cytokines (IL-1b, IL-6, and TNFa), and one growth factor
(VEGF). In arthritic synovium, a significant increase in
mRNA levels of MCP1, IL-1b, IL-6, TNFa, and VEGF was
observed as early as 7 hours after the antigenic challenge,
but the time course of gene expression varied with the
Figure 1 Time course of arthritis-related changes in rats with antigen-induced-arthritis. (a) Joint circumference of rat knees is estimated
from joint width (as described in Materials and methods). (b) Hind-paw weight distribution of arthritic rats is compared with that of saline-injected
controls. Data are expressed as percentage of weight distribution onto the right knee (sensitized with mBSA or saline-injected for control rats). (c)
Proteoglycan synthesis in patellar cartilage is measured by Na2
35SO4 incorporation. Data are expressed as the percentage of change in
35sulfate
incorporation in the central part of the patella. Data are mean ± standard error of the mean from 28 rats (a,b) or five samples (c). *P < 0.05
sensitized versus saline-injected knee. ≠P < 0.05 arthritic versus saline-injected rats. mBSA, methylated bovine serum albumin.















Day 0 1.0 ± 0.2 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.2 1.0 ± 0.4 1.0 ± 0.5 1.0 ± 0.1 1.0 ± 0.2 1.0 ± 0.2 1.0 ± 0.1
7 hours 13.9a ± 5.4 1.5 ± 0.6 30.2a ± 4.7 1.1 ± 0.2 5.13a ± 2.4 1.2 ± 0.5 3.8a ± 0.5 1.1 ± 0.2 35.0a ± 8.5 2.1 ± 1.0
Day 1 5.9a ± 1.9 1.1 ± 0.2 49.6a ±
29.4
1.0 ± 0.2 11.7a ± 5.2 1.1 ± 0.6 20.0a ±
12.2
1.1 ± 0.3 12.2a ± 2.6 1.2 ± 0.3
Day 2 6.3a ± 2.5 1.2 ± 0.4 23.4a ± 2.0 1.5 ± 0.5 0.4 ± 0.3 1.3 ± 0.7 3.7a ± 0.6 1.1 ± 0.3 157.5a ±
21.2
1.2 ± 0.3
Day 3 7.2a ± 2.7 1.1 ± 0.2 11.0* ± 2.7 1.1 ± 0.2 0.7 ± 0.5 1.1 ± 0.6 2.0 ± 0.4 1.0 ± 0.2 58.2a ± 6.4 1.4 ± 0.6
Day 7 3.3a ± 0.7 1.0 ± 0.2 5.9 ± 2.3 1.1 ± 0.2 0.3 ± 0.2 1.2 ± 0.6 0.7 ± 0.3 1.0 ± 0.2 79.7a ±
42.2
1.1 ± 0.3
Day 14 3.2a ± 1.4 1.1 ± 0.2 2.3 ± 0.3 1.0 ± 0.1 0.8 ± 0.5 1.1 ± 0.5 0.7 ± 0.2 1.0 ± 0.1 28.7a ± 7.1 1.3 ± 0.5
Rats were immunized subcutaneously with 0.5 g of methylated bovine serum albumin (mBSA) emulsified with complete Freund’s adjuvant 21 and 14 days prior
to articular injection (day 0) of 0.5 mg of mBSA (sensitized) or 50 μL of saline (contralateral) into the knee joints. Expression of mRNA was assessed before (on
day 0) and after (at 7 hours and on days 1, 2, 3, 7, and 14) sensitization. Data are expressed as delta delta threshold cycle (Ct) related to the housekeeping gene
(RP29). Values are the mean ± standard error of the mean of five independent measurements per time. aP < 0.05 in comparison with day 0. IL, interleukin; MCP-1,
monocyte chemoattractant protein-1; TNF-a, tumor necrosis factor-alpha; VEGF, vascular endothelial cell growth factor.
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mediator. MCP-1 mRNA level peaked (around 14-fold) at
7 hours and decreased quickly between D1 and D3 and
then slowly until D14. IL-1b, TNFa, and VEGF displayed a
comparable profile with a maximal induction by D1 (50-,
12-, and 20-fold increase, respectively) and a return to
normal level from D2 for TNFa and after D3 for the
others. In contrast, IL-6 mRNA level peaked by D2
(around 158-fold) and remained significantly elevated until
D14 (29-fold increase). None of the mediators displayed
any significant change in mRNA level in the synovium of
the saline-injected (contralateral) knee.
Overall pattern of mediator levels in biological fluids
As shown in Figure 2, the global analysis of arthritis-
induced changes in cytokine amounts were more marked
in SF than in the bloodstream, regardless of the func-
tional class considered. Mediators displayed two main
profiles of variation in arthritic joints, and cytokines
showed either an early and transient increase or a delayed
and sustained increase in their synovial contents. In gen-
eral, cytokine amounts increased earlier and more impor-
tantly in arthritic knees than in contralateral saline-
injected knees, although some mediators, such as IP-10,
IL-12p70, TNFa, or IL-5, failed to be affected signifi-
cantly by the arthritic process. A similar lack of change
was noted for the growth factors G-CSF and GM-CSF in
all biological fluids, whereas a marginal decrease of IL-4
and IL-10 levels was observed.
Cytokines with an early release in arthritic fluid
The amounts of the chemokines MIP-1a, MCP-1, GRO/
KC, eotaxin, and RANTES increased by 9-, 14-, 14-, 2-,
and 2-fold, respectively, in the SF of arthritic rats within
7 hours after the antigenic challenge (Figure 2). No sig-
nificant changes were observed in the SF of the contralat-
eral knee. In sera, GRO/KC, MCP-1, and RANTES levels
were also increased, although the range of induction
remained limited (2.7-, 2-, and 1.8-fold, respectively)
since these chemokines displayed a high circulating level
under basal conditions (Figure 3a,b,c). The intra-articular
peaks of mediator averaged 60 pg/knee for MCP-1 (Fig-
ure 3a), 45 pg/knee for GRO/KC (Figure 3b), 15 pg/knee
for RANTES (Figure 3c), and 5 pg/knee for eotaxin (Fig-
ure 3d). These chemokines returned to basal levels in
arthritic fluids and sera within D3, but a secondary flare
of RANTES release (2-fold change) was observed on D14.
The immunomodulatory cytokines IL-17 and IFNg
increased by 25- and 21-fold, respectively, in the SF of
arthritic rats within 7 hours after the antigenic challenge
(Figure 4a,c). However, both cytokines displayed a differ-
ent time course since IFNg returned to basal levels from
D1 after mBSA injection, whereas IL-17 levels declined
gradually until D14. No changes in cytokine amounts
were observed in the joint fluid from saline-injected
knees or in sera. IL-2 and IL-9 contents increased less
rapidly than IL-17 and IFNg in the arthritic knee (2- to
2.5-fold induction by D1) and showed a secondary but
non-significant increase by D7 (Figure 4b,d).
Cytokines with a sustained or a late release in arthritic
fluid
As early as 7 hours after arthritis induction, the amounts
of the proinflammatory cytokines IL-1b and IL-6
increased by 12- and 55-fold, respectively, in the SF of
sensitized joints (Figure 5a,c). However, IL-1 isoforms
displayed a distinct pattern of evolution since IL-1b levels
remained significantly elevated in arthritic joints until
D14 (Figure 5a) whereas IL-1a declined progressively
(Figure 2). The intra-articular peaks of mediators aver-
aged 150 pg/knee for IL-6 and 45 pg/knee for IL-1b
(Figure 5a,c), but no significant variation was noted in
corresponding sera. In arthritic fluid, the level of IL-18
and IL-13 increased only from D2 and D7 (2-fold
increase) until D14 (3- and 4-fold increases), respectively
(Figure 5b,d). However, an unexpected 2.2-fold increase
in IL-18 level was observed in the contralateral knee
from D1 to D2 after the antigenic challenge (Figure 5b).
Such variation was consistent with the transient release
of IL-18 into the bloodstream by D1.
Expression profile of selected growth factors
A delayed and sustained release of VEGF was observed in
the sensitized knees, and a 10-fold increase by D1 was fol-
lowed by a progressive lessening until D14 (Figure 2).
Despite its high circulating levels, leptin showed an
inverse evolution profile in arthritic SF but was signifi-
cantly increased by D14 in comparison with contralateral
knees.
Histological examination
As early as 7 hours after arthritis induction, synovium
was infiltrated by migrating cells, especially in the peri-
vascular areas of the sensitized knees (Table 2). A more
dedicated staining (May-Grünwald Giemsa) of blood
cells indicated infiltration by eosinophils in the knee as
early as 7 hours after arthritis induction (Figure 6). Inter-
estingly, though maximal at the earliest time point, the
perivascular infiltration paralleled the time course of the
diffuse infiltration of the tissue with a progressive lessen-
ing until D14. The only exception was the transient infil-
tration that was detected around the blood vessels before
D2 in the contralateral knees (Table 2). No other histolo-
gical finding was detected in contralateral knees through-
out disease duration. In sensitized knees, the additional
pathological changes were a progressive thickening of the
synovial cell layer from D1 to D14 and an overall tissue
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fibrosis. Interestingly, new blood vessel formation
occurred at a later time point (D3 to D7) in the inflamed
rat synovium. The scoring of cartilage lesions after safra-
nin O staining (Figure 7a) revealed a progressive loss of
proteoglycan in the sensitized knees (Figure 7c,d) and the
loss became significant from D2 to D14. A concomitant
bone loss was observed (Figure 7b,d) in comparison with
saline-injected knees (Figure 7b,c).
Discussion
The major aim of the present study was to analyze the
relevance of cytokine profiling to the pathophysiology of
experimental arthritis by combining the originality of a
sampling method of SF in rodents and the screening
capacity of a multiplex-based system. Indeed, despite the
classical use of the AIA model, the kinetics of mRNA
and mediator expression in arthritic joints remain
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Figure 2 Overall profiling of cytokines in joints and bloodstream of rats developing antigen-induced arthritis. Synovial fluid of both
knees - sensitized with methylated bovine serum albumin (mBSA) and saline-injected - and sera were collected at necropsy, and mediator levels
were measured by multiplex immunoassay. Results are expressed as fold of induction or of inhibition in comparison with day of sensitization
(day 0) (n = 5, representative of three independent experiments). Blue squares indicate that the corresponding mediator was at the basal level,
dark red squares indicate the maximal induction fold (50×), and purple squares indicate the maximal inhibition level (/5). D, day; G-CSF,
granulocyte colony-stimulating factor; GM-CSF, granulocyte macrophage colony-stimulating factor; GRO/KC, growth-related oncogene/
keratinocyte chemoattractant; H, hour; IFNg, interferon gamma; IL, interleukin; IP-10, inducible protein-10; MCP-1, monocyte chemoattractant
protein-1; MIP-1a, macrophage inflammatory protein-1-alpha; RANTES, regulated on activation normal T expressed and secreted; TNF-a, tumor
necrosis factor-alpha; VEGF, vascular endothelial cell growth factor.
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poorly characterized, whereas very few face-off studies
have been carried out between articular and circulating
mediator levels.
During the course of AIA, we confirmed that joint swel-
ling occurred early and peaked by D2, when the incapaci-
tation of the animal became maximal. Articular
incapacitation is assumed to result from the altered noci-
ception following injection of an inflammatory trigger into
the joints [29]. Although there can be some differences
between the use of zymosan, carrageenan, or LPS as
arthritis inducers, knee joint incapacitation is generally
thought to be supported by the release of bradykinin,
nitric oxide, eicosanoids, and/or proinflammatory cyto-
kines [30]. We describe - to our knowledge, for the first
time - a long-lasting joint incapacitation after a local anti-
genic challenge. The best correlation with the fast occur-
rence of abnormal weight bearing until D2 was found with
IL-2 (rs = 1) over VEGF, although the early peak release of
the chemokines MCP-1, MIP-1a, and GRO/KC and the
proinflammatory cytokines IL-1a or -b, IL-17, or IFNg
may have contributed to the initiation of incapacitation.
Nevertheless, at later time points, joint swelling lessened
progressively whereas abnormal weight bearing remained
at the same level, suggesting that pain persisted despite
the partial resolution of inflammation, likely as a result of
severe joint tissue remodeling. Because of its prominently
local character, AIA allows the analysis of cytokine pat-
terns in a locally driven immune response. We showed
that arthritis was characterized by an early transcriptional
activation of the chemokine MCP-1, the proinflammatory
cytokines IL-1b, IL-6, and TNFa, and the angiogenic fac-
tor VEGF in synovial tissue. For most cytokines, this early
induction of mRNA expression in the inflamed joint was
consistent with the early release of corresponding proteins
Figure 3 Synovial and circulating profiles of chemokines displaying an early increase in their joint levels during antigen-induced
arthritis. Expression of protein was assessed before the induction of antigen-induced arthritis (day 0) or afterwards (at 7 hours and on days 1, 2,
3, 7, and 14) in both arthritic (mBSA-sensitized) and contralateral (saline-injected) knees and in sera. Results are expressed as concentrations (in
picograms per milliliter) in serum and as quantity by knee (in picograms per knee) of the chemokines monocyte chemoattractant protein-1
(MCP-1) (a), growth-related oncogene/keratinocyte chemoattractant (GRO/KC) (b), regulated on activation normal T expressed and secreted
(RANTES) (c), or eotaxin (d). Values are the mean ± standard error of the mean of five independent samples. *P < 0.05 in comparison with day 0.
D, day; h, hour; mBSA, methylated bovine serum albumin.
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in the arthritic fluid. However, the transcriptional regula-
tion cannot be considered the unique mechanism respon-
sible for increased cytokine levels in physiological fluid,
since the release of proteins, notably chemokines,
appeared as early as 7 hours, suggesting the existence of
pools of mRNA or cytokine precursors (or both) which
were prone to be processed. In addition, the extent of
cytokine expression was much lower at the mediator than
the transcript level, and the release of IL-1b and IL-6 pre-
ceded the maximal increase in their mRNA levels, sup-
porting the possible contribution of rate-limiting steps
between both processes. One cannot rule out that very
early increase in mRNA may have preceded a rapid
decline due to mRNA instability or action of miRNA, as
has been suggested for IL-1b [31]. A similar observation
has been made for IL-6 in the murine air pouch model
that resembles the human synovial membrane. Indeed,
injection of monosodium urate in the pouch induced IL-6
expression in the first hour after challenge and before a
drastic decrease to basal levels between 4 and 9 hours
[32]. Therefore, we cannot rule out a transient and preco-
cious induction of IL-1b and IL-6 mRNA in our experi-
mental conditions.
As a consequence, the contribution of a given mediator
to arthritis could be overestimated when extrapolated only
from its mRNA level in inflamed joint tissues [20,21].
However, we observed a surprising uncoupling between
the early overexpression of TNFa in the inflamed syno-
vium and its stable low amount in the arthritic fluid,
despite previous reports of a lack of correlation between
mRNA and protein expression [21]. As TNFa-converting
enzyme is thought to be activated in rats developing
arthritis [33], especially in the early stage of the disease
[34], the low joint TNFa levels are unlikely to reflect a
defective processing of its mRNA. We suggest that these
low levels can reflect either a fast degradation of the cyto-
kine by proteases or the inability of the multiplex immu-
noassay to recognize TNFa when combined with soluble
receptors able to mask protein recognition by bead antibo-
dies. In line with such possible interference, protein arrays
Figure 4 Synovial and circulating profiles of immunomodulatory cytokines displaying an early increase in their joint levels during
antigen-induced arthritis. Expression of protein was assessed before the induction of antigen-induced arthritis (day 0) or afterwards (at 7 hours
and on days 1, 2, 3, 7, and 14) in both arthritic (mBSA-sensitized) and contralateral (saline-injected) knees and in sera. Results are expressed as
concentrations (in picograms per milliliter) in serum and as quantity by knee (in picograms per knee) of the immunomodulatory cytokines
interleukin-17 (IL-17) (a), IL-2 (b), and interferon-gamma (IFNg) (c) and IL-9 (d). Values are the mean ± standard error of the mean of five
independent samples. *P < 0.05 in comparison with day 0. D, day; h, hour; mBSA, methylated bovine serum albumin.
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were reported to be unable to detect IL-1a [35] or TNFa
[36] in culture supernatants, despite their use as the cell
challenging inflammatory stimulus. In experimental arthri-
tis, a pattern of soluble proteins is much more relevant
than a pattern of transcripts to pathological mechanisms
because most cytokines exert their biological effects in an
endocrine, paracrine, or juxtacrine way. From a practical
point of view, blood sampling is easy to perform and
Figure 5 Synovial and circulating profiles of mediators displaying a sustained or late increase in their joint levels during antigen-
induced arthritis. Expression of protein was assessed before the induction of antigen-induced arthritis (day 0) or afterwards (at 7 hours and on
days 1, 2, 3, 7, and 14) in both arthritic (mBSA-injected) and contralateral (saline-injected) knees and in sera. Results are expressed as
concentrations (in picograms per milliliter) in serum and as quantity by knee (in picograms per knee) of the proinflammatory cytokines
interleukin-1-beta (IL-1b) (a), IL-18 (b), or IL-6 (c) and the T helper 2 cytokine IL-13 (d). Values are the mean ± standard error of the mean of five
independent samples. *P < 0.05 in comparison with day 0. D, day; h, hour; mBSA, methylated bovine serum albumin.


















Day 0 0.2 ± 0.2 0.2 ± 0.2 0.6 ± 0.2 0.6 ± 0.3 0.6 ± 0.2 0.6 ± 0.3 0.4 ± 0.3 0.4 ± 0.3 0.0 ± 0.0 0.0 ± 0.0
7 hours 1.2 ± 0.4 0.2 ± 0.2 0.8 ± 0.4 0.6 ± 0.3 0.8 ± 0.2 0.8 ± 0.2 1.2a ± 0.2 0.8 ± 0.4 2.8a ± 0.6 1.6a ± 0.6
Day 1 1.6a ± 0.4 0.8 ± 0.2 1.6a ± 0.4 0.6 ± 0.3 0.6 ± 0.2 0.4 ± 0.2 2.2a ± 0.4 1.0 ± 0.0 2.0a ± 0.5 1.8a ± 0.4
Day 2 2a ± 0.3 0.2 ± 0.2 2.4a ± 0.3 0.6 ± 0.3 1.0 ± 0.0 0.6 ± 0.4 3.4a ± 0.3 0.4 ± 0.3 2.6a ± 0.5 0.4 ± 0.3
Day 3 3.2a ± 0.6 0.4 ± 0.3 2.2a ± 0.5 0.6 ± 0.3 1.8a ± 0.2 0.8 ± 0.4 3.4a ± 0.4 0.4 ± 0.3 2.0a ± 0.5 0.4 ± 0.3
Day 7 2.5a ± 0.7 0.3 ± 0.3 3.5a ± 0.3 0.3 ± 0.3 2.5a ± 0.5 0.5 ± 0.3 2.8a ± 0.6 0.3 ± 0.4 1.8a ± 0.5 0.4 ± 0.4
Day 14 3.3a ± 0.5 0.0 ± 0.0 4.0a ± 0.0 0.3 ± 0.3 1.8 ± 0.5 1.0 ± 0.4 2.0a ± 0.0 0.3 ± 0.3 1.8a ± 0.3 0.8 ± 0.3
Rats were immunized subcutaneously with 0.5 g of methylated bovine serum albumin (mBSA) emulsified with complete Freund’s adjuvant 21 and 14 days prior
to articular injection (day 0) of 0.5 mg of mBSA (sensitized) or 50 μL of saline (contralateral) into the knee joints. Values are expressed as the mean ± standard
error of the mean of five rats per time. aP < 0.05 in comparison with day 0.
Paquet et al. Arthritis Research & Therapy 2012, 14:R60
http://arthritis-research.com/content/14/2/R60
Page 10 of 15
a b 
Figure 6 Eosinophil infiltration in the synovium of rats developing antigen-induced arthritis. Representative sections of arthritic knee
(mBSA-injected) 7 hours after arthritis induction are shown. (a) Hematoxylin/eosin/safran staining (magnification 100×). (b) May-Grünwald
Giemsa (magnification 63×). Eosinophils are indicated by arrows. mBSA, methylated bovine serum albumin.
Figure 7 Histological grading of joint lesions in the knee joint of rats developing antigen-induced arthritis. (a) Cartilage score. (b) Bone
score. Data are expressed as mean ± standard error of the mean of five independent samples. ‡P < 0.05 in comparison with day 0.
Representative sections of contralateral (saline-injected) (c) and arthritic (mBSA-injected) (d) knees 14 days after arthritis induction (safranin O-fast
green staining, magnification 4×). D, day; h, hour; mBSA, methylated bovine serum albumin.
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circulating levels of mediators have been shown to predict
disease onset in humans [37] or to be indicative of a
patient’s response to biologics [38,39], especially when tak-
ing advantage of a multiplex analysis [15]. Some correla-
tions with disease activity were also reported in RA [40] or
experimental arthritis [41]. However, other studies support
the view that the local expression of cytokines may be the
best predictor of joint damage progression in humans [19]
and that blood levels do not necessarily correlate to clini-
cal response in animal models [21]. In addition, a multi-
plex analysis of SF demonstrated that the follow-up of
cytokine pattern allowed patients who had early RA and
subsequently developed RA to be distinguished from those
who had early RA but did not develop RA [42]. When we
performed a comparative kinetic study of mediator levels
in serum and SF, we confirmed that the expression pattern
was much more informative in joint fluid than in blood
[43]. Indeed, serum concentrations showed only little var-
iation during AIA, whereas some correlations were estab-
lished between cytokine concentrations in arthritic SF and
histological or clinical parameters. Such results are consis-
tent with the local and monoarticular nature of AIA [44],
rendering the amount of cytokines produced within a sin-
gle diseased joint prone to be reduced by degradation in
the lymphatic system or by dilution into the bloodstream
or both [45].
Chemokines were the first mediators to be overex-
pressed in biological fluids. However, MCP-1, GRO/KC,
and RANTES levels increased simultaneously in arthritic
SF and serum whereas MIP-1a and eotaxin were induced
only in sensitized knees during the first 24 hours of
arthritis. Chemokines play a key role in inflammation by
recruiting mononuclear leukocytes and lymphocytes in
inflamed knee joints [3,46,47]. Their expression was
clearly correlated to perivascular and diffuse infiltrates in
the synovial membranes of sensitized knees, in agreement
with their chemotactic potential [46]. Eotaxin is a chemo-
kine that is implicated in allergic responses [48] by
recruiting eosinophils. Its involvement in arthritic pathol-
ogies has not yet been demonstrated [49], but multiplex
analysis of plasma of patients with RA showed elevated
levels of eotaxin versus healthy controls [37]. Further-
more, the expression profile of eotaxin is very similar to
that of RANTES in inflamed SF. Previous studies showed
that RANTES played a fundamental role in the trafficking
and activation of leukocytes in arthritis establishment
[46,50] and that the use of RANTES antagonists could
lead to reduced joint inflammation [51,52]. We can spec-
ulate that eotaxin could be a potential target in RA treat-
ment. Eotaxin-2 is a potent chemoattractant for
eosinophils, basophils, and Th2 lymphocytes. Here, we
demonstrated the presence of eosinophils in arthritic
joints in the first hours of arthritis development, whereas
eosinophils were reported to be absent from the
synovium ofpatients with late-stage arthritis [53]. But in
their observations, Tetlow and Woolley [53] did not
exclude the possibility that eosinophils show a transient
and rapid infiltration of rheumatoid synovial tissue at
earlier stages of disease activity. Furthermore, RA is con-
sidered a heterogeneous disease, as treatments targeting
different pathogenic pathways such as neutralization of
TNF-a or depletion of B cells are not effective in all
patients. It is likely that patients with resistant RA may
have other types of disease, and one uncommon type of
RA is associated with hypereosinophilia, which correlates
to arthritis severity [54]. GRO/KC is a CXC chemokine
whose pathogenic role is poorly described in arthropa-
thies but displayed an interesting expression profile in
the AIA model. MCP-1, RANTES, and MIP-1a are pro-
duced in inflamed knees [46,55,56] and act in the recruit-
ment of phagocytic leukocytes during inflammation.
Globally, chemokine induction in SF is positively corre-
lated with joint swelling in the early phase of arthritis
and synovium infiltration observed at histological
examination.
Proinflammatory cytokines also increased early in SF of
arthritic knees. IL-1a and IL-1b are expressed very pre-
cociously and can be linked to the proteoglycan anabo-
lism loss observed in patellar cartilage, and IL-1b has a
key role in the regulation of proteoglycan metabolism
[11]. Biotherapies targeting IL-1b have already shown
their efficacy in inflammation healing [10] by using either
antibodies or antagonist receptor (IL-1Ra). Bone remo-
deling was observed and was correlated to IL-1b [9,22]
and IL-6 expression patterns. IL-6 was also expressed
early and at very high levels in SF and remained elevated
during the course of this model. IL-6 is now considered
as one of the most important mediators of the acute-
phase response. As previously discussed, we failed to
observe any significant modifications of TNF-a level dur-
ing the course of AIA; nevertheless, its pivotal role in
AIA establishment was demonstrated by the efficacy of
anti-TNF-a in this model [57]. Previous studies showed a
maximum of induction 6 hours after arthritis induction
but this measure was performed on synovial membrane
homogenates, and consequently the measured TNF-a
level addressed both transmembrane and extracellular
mediators. IL-1b, IL-6, and TNFa are elevated in human
RA synovium and have also been shown to contribute to
the development of arthritis in animal models [4,58].
IL-18 belongs to the IL-1 family and is processed like IL-
1b by the inflammasome [59] but presented a different
expression profile in SF. Surprisingly, we observed an
increase in the contralateral knee at 7 hours. Because of
the prominently local character of AIA, it is commonly
accepted that each rat could be its own control, since only
the antigen-injected joint develops inflammation. Never-
theless, this observation points out that the contralateral
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knee may favor misinterpretation of the data when consid-
ered as the healthy control [57].
In sensitized knees, IL-18 level was progressively
increased. IL-18 is thought to play a major role in the
chronicity of inflammation in this arthritis model. Recent
publications have demonstrated the importance of this
cytokine in allergies [60] and arthritic pathologies [10].
Although IL-18 is also known to act synergistically with
IL-12, we did not observe correlations between these two
cytokines in SF during AIA. IL-18 was also known as an
IFNg-stimulating factor [61], but we observed two dis-
tinct expression profiles for IFNg and IL-18 in this study.
Immunomodulatory cytokines play a major role in RA.
Indeed, in this experimental model, we observed that
IFNg and IL-2 were expressed in SF, and only in the first
hours after sensitization.
Until recently, arthritis was considered a Th1 pathology,
but now arthritis is known to be mainly IL-17-dependent
[62]. Many studies are actually conducted to target IL-17
in arthritis models [62,63] because of its potential synergis-
tic effects with IL-1b, IL-6, and TNF-a in inducing cyto-
kine expression and joint damage [64]. The expression
profile of IL-17 was the same as that of IL-1b, and IL-17
cytokine may also contribute to inhibition of proteoglycan
anabolism [65].
In regard to growth factors, VEGF was expressed after
24 hours and the histological analysis revealed an
increased number of blood vessels in the synovium after 4
days, consistently with the promotion of neoangiogenesis
by this cytokine [66]. Levels of G-CSF and GM-CSF did
not show significant variations, and their importance
seems limited in this experimental arthritis model, even if
their antagonists have shown anti-inflammatory effects in
other murine experimental models [67,68]. Sera leptin
decreased significantly after 3 days and then returned to
its original high level, whereas in SF, an increase was
observed after 14 days, indicating the potential role of this
adipokine in arthritis chronicity and bone degradation in
the long term. There is a consensus about its pivotal role
as a proinflammatory, bone metabolism regulating, and
immune-modulating agent. Nevertheless, its mechanisms
of action have not been fully described [69].
We observed, in SF, a progressive increase in the
amount of IL-13, a cytokine usually described in allergic
reactions and pulmonary fibrosis [70]. However, the pat-
tern of IL-4 was different from that of IL-13. Although
IL-13 and IL-4 are both central Th2 cytokines in the
immune system and potent activators of inflammatory
responses and fibrosis during Th2 inflammation, recent
studies demonstrated that these cytokines exerted a dis-
tinct role in asthma pathology [71]. One can suppose
that IL-13 rather than IL-4 plays a prominent role in the
synovial membrane fibrosis observed here since a positive
chronic correlation exists between IL-13 and fibrosis
(Spearman correlation). Another cytokine not described
in arthritis but known for its cell proliferation capacities
[72], IL-9, was expressed early in sensitized knees. Both
cytokines may play a role in synovial hyperplasia, which
is a major event in RA. Further studies will be required
to confirm this hypothesis.
Conclusions
The present study is the first kinetic study (from 7 hours to
14 days) of 24 SF cytokines profiled in a complete biochem-
ical, histological, and clinical arthritis model. Previous stu-
dies on animal models focused on a restricted number of
cytokines [21] and were assessed on synovial extract or
joint homogenates (which contain both inactive cytokine
precursors and active cytokines) [20]. Using this technol-
ogy, we observed that SF cytokine amounts are correlated
to biochemical, histological, and clinical parameters of
arthritis in a timely fashion. Moreover, we established
expression patterns of cytokines - besides the mediators
known to be involved in arthritis - that are poorly described
in articular physiopathology. The analysis provided here
may allow the further study of molecular mechanisms
involved in the establishment and evolution of autoimmune
arthritis, leading to potential new clinical therapies [73].
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